



#38/I

PATENT
Attorney Docket No. 219490
DHHS Ref. No. E-221-95/0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Topalian et al.

RECEIVED

Application No. 08/533,895

Art Unit: 1644

NOV 26 2002

Filed: September 26, 1995

Examiner: A. DeCloux TECH CENTER 1600/2900

For: MHC CLASS II RESTRICTED
MELANOMA ANTIGENS AND
THEIR USE IN THERAPEUTIC
METHODS

AMENDMENT AND RESPONSE TO OFFICE ACTION

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated June 17, 2002, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 64-67, 69, 70, 72-75, 77, 78, 80, 81, 83, 84, 86, 87, 89, 90, and 94-99 without prejudice.

Please add the following new claims:

100. (New) An isolated immunogenic peptide consisting essentially of amino acids 56-70 of SEQ ID NO: 39 or amino acids 448-462 of SEQ ID NO: 39, or a derivative of either of the foregoing, wherein the amino acid sequence of the derivative is at least 85% identical with the immunogenic peptide, wherein the immunogenic peptide or derivative thereof is recognized by a CD4⁺ T lymphocyte, which is restricted by a Major Histocompatibility Complex (MHC) Class II molecule.

08533895

11/25/2002 MBL/ANCD 00000010 121216

01 FC:1252 400.00 CH